Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuroone Medical Technologies (NMTC) Other financing activities (2016 - 2025)

Neuroone Medical Technologies posted quarterly Other financing activities of $22920.0 for Q4 2025, up 7.58% year-on-year from $21305.0 in Q4 2024, and up 7.58% on a QoQ basis from $21305.0 in Q4 2024.

Neuroone Medical Technologies (NMTC) has 8 years of Other financing activities data on file, last reported at $22920.0 in Q4 2025.

  • For the quarter ending Q4 2025, Other financing activities rose 7.58% year-over-year to $22920.0; the trailing twelve-month figure through Mar 2026 stood at -$172374.0 (changed N/A YoY), and the FY2024 full-year result was $20000.0, down 91.48% from the prior year.
  • Other financing activities for Q4 2025 stood at $22920.0, up from $21305.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $183359.0 in Q1 2023 and bottomed at -$216599.0 in Q3 2024.
  • The 4-year median for Other financing activities is $37698.0 (2023), against an average of $34962.6.
  • The widest annual swing landed in 2023, when Other financing activities surged 139.92%; it then tumbled 43.49% in 2024.
  • A 4-year view of Other financing activities shows it stood at $15713.0 in 2022, then soared by 139.92% to $37698.0 in 2023, then sank by 43.49% to $21305.0 in 2024, then advanced by 7.58% to $22920.0 in 2025.
  • The last three Other financing activities figures came in at $22920.0 (Q4 2025), $21305.0 (Q4 2024), and -$216599.0 (Q3 2024), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn
10 Neuroone Medical Technologies 31.39 Mn 28.59 Mn 1.29 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 22,920.00
Dec 31, 2025 22,920.00
Dec 31, 2024 21,305.00
Dec 31, 2024 21,305.00
Sep 30, 2024 -216,599.00
Sep 30, 2024 -216,599.00
Jun 30, 2024 50,519.00
Jun 30, 2024 50,519.00
Mar 31, 2024 148,382.00
Mar 31, 2024 148,382.00
Dec 31, 2023 37,698.00
Dec 31, 2023 37,698.00
Jun 30, 2023 51,366.00
Jun 30, 2023 51,366.00
Mar 31, 2023 183,359.00
Mar 31, 2023 183,359.00
Dec 31, 2022 15,713.00
Dec 31, 2022 15,713.00
Jun 30, 2020 633,724.00
Jun 30, 2020 633,724.00
Dec 31, 2019 417,176.00
Dec 31, 2019 417,176.00
Dec 31, 2017 1,871.00
Dec 31, 2017 1,871.00
Mar 31, 2017 4,870.00
Mar 31, 2017 4,870.00
Dec 31, 2016 25,694.00
Dec 31, 2016 25,694.00